HCW Biologics (NASDAQ:HCWB) Trading Down 2.5% – Here’s Why

HCW Biologics Inc. (NASDAQ:HCWB) fell 2.5% during mid-day trading on Monday . The stock traded as low as $0.43 and last traded at $0.45. 9,672 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 19,655 shares. The stock had previously closed at $0.46.

HCW Biologics Stock Performance

The firm has a fifty day simple moving average of $0.52 and a 200-day simple moving average of $0.80. The company has a quick ratio of 0.10, a current ratio of 0.10 and a debt-to-equity ratio of 0.95. The company has a market cap of $17.06 million, a PE ratio of -0.59 and a beta of 0.80.

HCW Biologics (NASDAQ:HCWB) last announced its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $0.62 million during the quarter. HCW Biologics had a negative net margin of 978.03% and a negative return on equity of 385.90%.

Hedge Funds Weigh In On HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Pullen Investment Management LLC bought a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 85,116 shares of the company’s stock, valued at approximately $149,000. Pullen Investment Management LLC owned approximately 0.23% of HCW Biologics at the end of the most recent quarter. 2.96% of the stock is currently owned by institutional investors and hedge funds.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.